

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Assistant Commissioner for Patents,  
Washington, D.C. 20231 on March 5, 2003.

David Saliwanchik

David R. Saliwanchik, Patent Attorney

SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT  
Examining Group 1636  
Patent Application  
Docket No. SPO-112  
Serial No. 09/762,842

TECH CENTER 1600/2900

MAR 14 2003

RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Art Unit : 1636  
Applicants : Murasugi Akira, Asami Yukio, Kido Isao and Kumai Hideshi  
Serial No. : 09/762,842  
Filed : February 12, 2001  
Conf. No. : 1096  
For : High Level Secretory Expression System of Intact MK Family Protein

Assistant Commissioner for Patents  
Washington, D.C. 20231

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT  
UNDER 37 CFR §§1.97 AND 1.98


Sir:

In accordance with 37 CFR §1.56, the references listed on the attached form PTO/SB/08 are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. Copies of the cited documents are enclosed.

The undersigned hereby certifies that the items of information contained in this statement were cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

The Applicants respectfully assert that the substantive provisions of 37 CFR §§1.97 and 1.98 are met by the foregoing statement.

Respectfully submitted,



David R. Saliwanchik  
Patent Attorney  
Registration No. 31,794  
Phone No.: 352-375-8100  
Address : 2421 N.W. 41st Street, Suite A-1  
Gainesville, FL 32606-6669

DRS/la

Enclosures: Form PTO/SB/08; and  
Copies of references cited therein.



Under the Patent and Trademark Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

2

### Complete if Known

Application Number	09/762,842
Filing Date	February 12, 2001
First Named Inventor	Murasugi Akira
Art Unit	1636
Examiner Name	Unknown
Attorney Docket Number	SPO-112

TECH CENTER 1600 MAR 14 2003  
1600/2000

RECEIVED

### U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
U1	US-5,324,639		06-28-1994	Brierley et al	All
U2	US-				
U3	US-				
U4	US-				
U5	US-				
U6	US-				
U7	US-				
U8	US-				
U9	US-				
U10	US-				
U11	US-				
U12	US-				
U13	US-				
U14	US-				
U15	US-				
U16	US-				
U17	US-				
U18	US-				
U19	US-				
U20	US-				

### FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
	F1					
	F2					
	F3					
	F4					
	F5					
	F6					
	F7					
	F8					
	F9					
	F10					

Examiner Signature		Date Considered
--------------------	--	-----------------

\*EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04 <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST3) <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO Assistant Commissioner for Patents, Washington, DC 20231.



Under the ~~Patent~~ Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031  
U S Patent and Trademark Office U S DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

2

of

2

### Complete if Known

Application Number	09/762,842
Filing Date	February 12, 2001
First Named Inventor	Murasugi Akira
Group Art Unit	1636
Examiner Name	Unknown
Attorney Docket Number	SPO-112

### NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article. (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	R1	BRANKAMP, R., et al., "Expression of a Synthetic Gene Encoding the Anticoagulant-Antimetastatic Protein Ghilanten by the Methylotrophic Yeast <i>Pichia pastoris</i> ", <i>Protein Expression and Purification</i> , 1995, pp. 813-820, Vol. 6, Academic Press, Inc.	
	R2	MURASUGI, A. and TOHMA-AIBA, Y., "Characterization of Partially Truncated Human Midkine Expressed in <i>Pichia pastoris</i> ", <i>Biosci. Biotechnol. Biochem.</i> , June 2002, pp. 1295-1300, Vol. 66, No. 6.	
	R3	MURASUGI, A. and TOHMA-AIBA, Y., "Comparison of Three Signals for Secretory Expression of Recombinant Human Midkine in <i>Pichia pastoris</i> ", <i>Biosci. Biotechnol. Biochem.</i> , October 2001, pp. 2291-2293, Vol. 65, No. 10.	
	R4	ROSENFIELD, S., et al., "Production and Purification of Recombinant Hirudin Expressed in the Methylotrophic Yeast <i>Pichia pastoris</i> ", <i>Protein Expression and Purification</i> , December 1996, pp. 476-482, Vol. 8, No. 4, Academic Press, Inc.	
	R5	SREEKRISHNA, K., et al., "Strategies for Optimal Synthesis and Secretion of Heterologous Proteins in the Methylotrophic Yeast <i>Pichia pastoris</i> ", <i>Gene</i> , April 29, 1997, pp. 55-62, Vol. 190, No. 1, Elsevier Science B.V.	
	R6	UEHARA, K., et al., "Genomic Structure of Human Midkine (MK), a Retinoic Acid-Responsive Growth/Differentiation Factor", <i>J Biochem</i> , May 1992; pp. 563-567, Vol. 111, No. 5.	
	R7		
	R8		
	R9		
	R10		
	R11		
	R12		
	R13		

TECH CENTER 1600  
RECEIVED  
MAR 14 2003  
2000

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

<sup>1</sup> Applicant's unique citation designation number (optional) <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached

Burden Hour Statement This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U S Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO Assistant Commissioner for Patents, Washington, DC 20231.